Trial Profile
A Phase 3 Multinational, Multi-center, Single-arm, Open-label Study for the Efficacy and Safety of Radotinib in Ph+ Chronic Phase Chronic Myeloid Leukemia Patients With Failure or Intolerance to Previous TKIs Therapy Including Imatinib
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Jan 2022
Price :
$35
*
At a glance
- Drugs Radotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Sponsors Il-Yang
- 03 Jan 2022 Planned End Date changed from 1 Apr 2023 to 1 Apr 2025.
- 03 Jan 2022 Planned primary completion date changed from 15 Mar 2022 to 29 Jan 2025.
- 19 Mar 2020 Planned End Date changed from 1 Apr 2022 to 1 Apr 2023.